Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-P3 long-term alpelisib study in PROS after EPIK-P1
2023-508522-95-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of alpelisib in PIK3CA-related overgrowth spectrum (PROS) (2 arms), sponsored by Novartis. Primary endpoint: Incidence of new or worsening grade 3 or higher treatment-emergent adverse events. Planned start Jan 2022; status: authorised.
02
Drugs
alpelisib
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on 2023-508522-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508522-95-00.